US007772209B2

(12) **United States Patent**
Niyikiza

(10) **Patent No.: US 7,772,209 B2**
(45) **Date of Patent: Aug. 10, 2010**

(54) **ANTIFOLATE COMBINATION THERAPIES**

(75) Inventor: **Clet Niyikiza**, Indianapolis, IN (US)

(73) Assignee: **Eli Lilly and Company**, Indianapolis, IN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 162 days.

(21) Appl. No.: **11/776,329**

(22) Filed: **Jul. 11, 2007**

(65) **Prior Publication Data**

US 2008/0032948 A1 Feb. 7, 2008

Related U.S. Application Data

(62) Division of application No. 11/288,807, filed on Nov. 29, 2005, now abandoned, which is a division of application No. 10/297,821, filed as application No. PCT/US01/14860 on Jun. 15, 2001, now Pat. No. 7,053,065.

(60) Provisional application No. 60/215,310, filed on Jun. 30, 2000, provisional application No. 60/235,859, filed on Sep. 27, 2000, provisional application No. 60/284,448, filed on Apr. 18, 2001.

(51) **Int. Cl.**

A61K 31/70	(2006.01)
A61K 31/685	(2006.01)
A61K 31/50	(2006.01)
A61K 31/525	(2006.01)
A61K 31/519	(2006.01)

(52) **U.S. Cl.** **514/52**; 514/77; 514/249; 514/251; 514/265.1

(58) **Field of Classification Search** 514/52, 514/77, 249, 251, 265.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,920,015	A	1/1960	Thompson	
4,140,707	A *	2/1979	Cleare et al.	556/137
5,344,932	A	9/1994	Taylor	
5,405,839	A	4/1995	Toraya et al.	
5,431,925	A	7/1995	Ohmori et al.	
5,563,126	A	10/1996	Allen et al.	
5,736,402	A	4/1998	Francis et al.	
6,207,651	B1	3/2001	Allen et al.	
6,297,224	B1	10/2001	Allen et al.	
6,528,496	B1	3/2003	Allen et al.	
7,053,065	B2	5/2006	Niyikiza et al.	
2003/0216350	A1	11/2003	Allen et al.	
2003/0225030	A1	12/2003	Allen et al.	
2004/0005311	A1	1/2004	Pitman	

FOREIGN PATENT DOCUMENTS

EP	0 546 870	6/1993	
WO	WO 95/27723	10/1995	

OTHER PUBLICATIONS

Calvert H.: "Folate status and the safety profile of antifolates", Seminars in Oncology, 2002, 29/2 Suppl. 5, pp. 3-7, XP008005755.

Calvert H.: "Future directions in the development of pemetrexed", Seminars in Oncology, 2002, 29/2 Suppl. 5, pp. 54-61, XP008005744.

Westerhof, et al: "Carrier-and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecularstructure and biological activity", Mol. Pharmacology, 1995, 48(3), pp. 459-471, XP008005762.

Worzalla, et a]: "Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514", Anticancer Research (1998), 18(5A), pp. 3235-3239, XP008005757.

Hanauske, et al: "Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors", Oncologist, Alphamed Press, US, vol. 4, No. 6, 2001, pp. 363-373, XP008005751.

Bunn, et al: "Vitamin B 12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY 231514, MTA), a novel antifolate/antimetabolite", Program/Proceedings—American Society of Clinical Oncology, the Society, US, vol. 76A, No. 20, 2001, p. 300, XPO08005885.

Dierkes, et al., Supplementation with Vitamin B 12 Decreases Homocystein and Methylmalonic Acid but Also Serum Folate in Patients with End-Stage Renal Disease. Metabolism. May 1999. vol. 48, No. 5, pp. 631-635. See: abstract.

Arsenyan et al. (Abstract: Onkol. Nauchn., (1978) 12(10):49-54.

John, et al. (Cancer 2000, 88: 1807-13).

Poydock et al., "Growth-inhibiting effect of hydroxocobaltniin and L-ascorbic acid on two solid tumors in mce", IRCS Medical_ Science, vol. 12, No. 9, pp. 813 (1984).

The Cecil Reference, Textbook of Medicine, 21st Edition (2000). Chapter 198. pp. 1060-1074.

Poydock M. Effect of combined ascorbic acid and B-12 on survival of mice with implanted Ehrlich carcinoma and L1210 leukemia. *Am J Clin Nutr* 1991; 54: 1261S-5S.

Poydock M, et al. Mitogenic inhibition and effect on survival of mice bearing L1210 leukemia using a combination of dehydroascorbic acid and hydroxycobalamin. *Am J Clin Oncol* 1985; 8: 2666-269.

Poydock M, et al. Influence of Vitamins C and B12 on the Survival Rate of Mice Bearing Ascites Tumor. *Expl Cell Biol* 1982; 50:88-91.

Toohey J. Dehydroascorbic acid as an anti-cancer agent. *Cancer Letters* 2008; 263:164-169.

Sallah S, et al. Intrathecal methotrexate-induced megaloblastic anemia in patients with acute leukemia. *Archives of Pathology & Laboratory Medicine* 1999; 123(9): 774-777.

Nishizawa Y, et al. Effects of methylcobalamin on the proliferation of androgen-sensitive or estrogen-sensitive malignant cells in culture and in vivo. *International Journal for Vitamin and Nutrition Research* 1997; 67(3):164-170.

(Continued)

Primary Examiner—Kevin Weddington
(74) *Attorney, Agent, or Firm*—Elizabeth A. McGraw

(57) **ABSTRACT**

A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.

22 Claims, No Drawings